Market expansion Minomic is actively expanding MiCheck Prostate into new territories beyond the USA and Australia, presenting a growth opportunity to partner with local distributors, labs, and healthcare networks in regions with rising demand for high-specificity prostate cancer diagnostics.

Clinical credibility With a reported 95% sensitivity and superior specificity reducing unnecessary biopsies, there is a sales angle to emphasize cost savings and improved patient pathways to healthcare buyers, payers, and hospital systems seeking value-based diagnostics.

Strategic partnerships Existing commercialization through high-complexity CLIA labs in Maryland and Sonic Healthcare in Australia indicates a successful partner model; targeting additional lab networks, academic medical centers, and referral pathways could accelerate adoption.

Evidence pipeline Publications and clinical study backing MiCheck Prostate provide material for sales enablement; opportunities exist to sponsor or align with ongoing trials, webinars, and key opinion leader events to drive awareness among urologists and oncologists.

Digital reach Current tech stack and digital presence (HubSpot, WordPress, Shopify, Mailchimp, Azure) enable targeted digital campaigns, lead nurturing, and e-commerce style ordering for clinics; leverage for multi-territory lead generation and partner onboarding.